Please Wait.....
Report
Indonesia Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
Market Report I 2026-01-16 I 70 Pages I Mordor Intelligence
Indonesia Diabetes Drugs Market Analysis
The Indonesia Diabetes Drugs market is expected to grow from USD 387.13 million in 2025 to USD 411.33 million in 2026 and is forecast to reach USD 556.85 million by 2031 at 6.25% CAGR over 2026-2031.
The steady climb is underpinned by the country's status as the world's fifth-largest diabetes population, universal insurance coverage through BPJS Kesehatan, and expanding local manufacturing capacity. Prescription volumes keep rising as older adults account for most new diagnoses, while novel GLP-1 and SGLT-2 agents win clinical acceptance in urban hospitals. Greater domestic production of active pharmaceutical ingredients (APIs), a push toward halal-certified drugs, and aggressive digital-health roll-outs add further momentum to the Indonesia diabetes drugs market.
Indonesia Diabetes Drugs Market Trends and Insights
Rising Diabetes Prevalence & Aging Population
Indonesia's adult diabetes prevalence jumped to 11.7% in 2024, up from 5.1% in 2011, with half of all diagnoses in the 65-74 age bracket. This long-running demographic shift fuels consistent demand across every therapeutic class and sets a stable volume base for the Indonesia diabetes drugs market. The Ministry of Health plans a sugar-tax framework to curb sweet-beverage intake, yet treatment needs remain high as lifestyle patterns change slowly. Epidemiological studies also link diabetes with higher incidences of heart, liver, and lung disease, pushing clinicians toward combination regimens that manage multiple comorbidities. These realities keep the treatment pipeline accelerating, particularly for age-tailored fixed-dose combinations that simplify daily adherence.
Government Initiatives and Insurance Programs
BPJS Kesehatan currently reimburses diabetes drugs under a unifi ed benefits schedule that reaches more than 200 million citizens. Starting 2025, an allocated Rp 3.3 trillion budget for free annual medical check-ups will likely raise early diagnosis volumes, enlarging the Indonesia diabetes drugs market. New chronic-disease screening regulations oblige primary-care clinics to follow structured follow-up protocols, maintaining steady prescription flows beyond initial diagnosis. A mandatory Standard Inpatient Class (KRIS) regime, due July 2025, eliminates tiered hospital benefits and thus levels access to newer diabetes therapies across income groups. Together, these policies close coverage gaps while nudging prescription decisions toward guideline-compliant brands.
90% API Import Dependence Inflates COGS
Local firms still source most raw materials from China and India, exposing supply chains to currency swings and freight bottlenecks. While Java's new API plants reduce vulnerability, capacity remains insufficient to cover nationwide demand, keeping unit costs elevated relative to regional peers.
Other drivers and restraints analyzed in the detailed report include:
Uptake of Novel GLP-1 & SGLT-2 TherapiesGrowing Penetration of Branded-GenericsHigh Out-of-Pocket Cost for Analogue Insulin
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
The Indonesia diabetes drugs market size for oral therapies reached USD 162.79 million in 2025, equal to a 42.05% revenue slice. Metformin (33.85% prescription rate) and glimepiride dominate first-line choices, aided by inclusion on the national e-Fornas list. Uptake of fixed-dose combinations is rising as physicians seek one-pill dosing to reinforce adherence among multi-morbidity seniors. In parallel, non-insulin injectables book the fastest trajectory, with an 8.45% CAGR linked to GLP-1 and dual-agonist trial activity. LeaderMed and Combiphar's Phase 3 study of LM-008-from September 2024-underscores local appetite for next-generation injectables. Premium analogue insulin retains a narrow but lucrative share because 35% of users prefer premixed pens for convenience.
Intensified competition around value-added injectables changes hospital formularies, especially in Jakarta and Bandung, where specialist panels now weigh cardiovascular-outcome data more heavily. Pharmaceutical groups answer with patient-assistance schemes and bundled glucometer packages, tactics that deepen loyalty but squeeze margins. Local API plants could improve gross margins for oral tablets; however, complex peptides for injectables still depend on imported intermediates, limiting immediate price relief.
The Indonesia Diabetes Drugs Market Report is Segmented by Drug Class (Oral Anti-Diabetics, Insulins, Combination Drugs and Non-Insulin Injectable Drugs), Diabetes Type (Type-1 Diabetes and Type-2 Diabetes), and Distribution Channel (Hospital Pharmacies, Retail Chain Pharmacies and Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Novo Nordisk PT Kalbe Farma Tbk Sanofi Eli Lilly and Company Merck AstraZeneca Boehringer Ingelheim Takeda Pharmaceuticals Pfizer Janssen Lupin Novartis GlenmarkPharmaceuticals PT Dexa Medica PT Kimia Farma Tbk PT Phapros Tbk Astellas Pharma
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Diabetes Prevalence & Aging Population
4.2.2 Government Initiatives and Insurance Programs
4.2.3 Uptake of Novel GLP-1 & SGLT-2 Therapies
4.2.4 Growing Penetration of Branded-Generics
4.2.5 Improved Medical Education and Clinical Guidelines
4.2.6 Local Manufacturing Partnerships and Local "fill-and-finish" Insulin Partnerships
4.3 Market Restraints
4.3.1 90 % API Import Dependence Inflates COGS
4.3.2 High Out-of-pocket Cost for Analogue Insulin
4.3.3 Physician CME Gap Slows Adoption of New Drugs
4.3.4 Patent-cliff Uncertainty Deters Local Investors
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technology Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Drug Class
5.1.1 Oral Anti-Diabetic Drugs
5.1.2 Insulins
5.1.3 Combination Drugs
5.1.4 Non-Insulin Injectables
5.2 By Diabetes Type
5.2.1 Type 1 Diabetes
5.2.2 Type 2 Diabetes
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Chain Pharmacies
5.3.3 Online Pharmacies
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.3.1 Novo Nordisk A/S
6.3.2 PT Kalbe Farma Tbk
6.3.3 Sanofi
6.3.4 Eli Lilly and Company
6.3.5 Merck & Co.
6.3.6 AstraZeneca
6.3.7 Boehringer Ingelheim
6.3.8 Takeda
6.3.9 Pfizer
6.3.10 Janssen Pharmaceuticals
6.3.11 Lupin
6.3.12 Novartis
6.3.13 Glenmark
6.3.14 PT Dexa Medica
6.3.15 PT Kimia Farma Tbk
6.3.16 PT Phapros Tbk
6.3.17 Astellas
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security